Increasing prevalence and incidence of chronic diseases such as diabetes, hormonal disorder, and reproductive health issues are the factors that are driving the injectable drug delivery device market. Additionally, factors such as the need for patient-controlled drug release and increased risk of needle stick injuries are driving the injectable drug delivery market. The major advantage of injecting the drug is it enables the rapid transport of drug into the body through by-passing the first-pass metabolism and it facilitates the management of the drugs in comatose patients. It is widely used in different conditions that include cystic fibrosis, pain, hormonal imbalance, hepatitis C, autoimmune diseases, ribose-5-phosphate isomerase deficiency, and Wilson diseases. The two types of devices are used for injecting drugs that are conventional and self-injectable drug delivery devices. The drug delivery devices include pen injectors, needle-free injector, and auto-injectors. The auto-injector such as adrenaclick, Auvi-Q, Semjepi, and EpiPen. The needle-free injector includes gas-based needle-free injectors and spring-based needle-free injectors.
Browse
the full report description Global Injectable Drug Delivery Device Market Size,
Share & Trends Analysis Report by Device Type (Conventional Drug Delivery
Devices and Self-Injectable Drug Delivery Devices), by Application (CVD,
Diabetes, Oncology, General Medication, Vaccination, and Others), by End-User
(Hospitals, Ambulatory Centers, Clinics, and Homecare) and Forecast 2019-2025
at
Moreover, the increase in technological advancement and innovation are driving the demand for injectable drug delivery market across the globe. Introduction of dual injectable drug delivery system has offered several advantageous functions and features that enhance safety, efficacy, compliance and usability and functions includes diagnostics and connectivity. The companies have introduced advanced devices to deliver drugs. For instance, in January 2019, Sandoz Inc., and Novartis announced the introduction of SYMJEPI injection for the treatment of allergic reactions type1 including allergen immunotherapy, drugs, diagnostic testing substance, and foods. The company launched medicine as a single dose. In 2018, AbbVie and Eisai have launched the HUMIRA an auto-injector formulation. It is the world human anti-TNF monoclonal antibody and it plays a vital role in the inflammatory response of autoimmune diseases, which includes rheumatoid arthritis.
Injectable drug delivery market is highly fragmented due to the presence of several market players that are signi ficantly operating across the globe. Some of the key players of the injectable drug delivery market include Cardinal Health, Inc., Gerresheimer AG, Schott AG, Becton, Dickinson and Co., Wilhelm Haselmeier GmbH & Co. KG, and Pfizer Inc. These market players provide a drug delivery system having industry-leading needle technologies, safety and shielding system, prefillable syringes and self-injection systems for hospitals, clinics, and homecare.
Current market trends report covered in the market report:
Global Injectable Drug Delivery Device Market – Segmentation
By Device Type
By Application
• Others (Autoimmune Disorders)
By End-User
Global Injectable Drug Delivery Device Market –Segment by region
North America
Europe
Asia-Pacific
Rest of the World
To
learn more about this report request a free sample copy @